Fingerprint
Dive into the research topics of 'Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically